BioTech
バイオテック・ライフサイエンスVC一覧。治療薬、診断、計算生物学、創薬、合成生物学、バイオ製造まで。シード〜シリーズC創業者向けにステージ別でフィルタリング可能。
16
20
0
BioTech に投資するトップVC
すべてのVCを見る →Founders Fund
San Francisco, CA
Khosla Ventures
Menlo Park, CA
SBI Investment
Tokyo, Japan
ANRI
Tokyo, Japan
UTEC
Tokyo, Japan
Lux Capital
New York, NY
Andreessen Horowitz Bio Fund
Menlo Park, CA
OrbiMed
New York, NY
ARCH Venture Partners
Chicago, IL
Polaris Partners
Boston, MA
Atlas Venture
Cambridge, MA
F-Prime Capital
Boston, MA
Prime Movers Lab
Jackson, WY
Fifty Years
San Francisco, CA
DCVC (Data Collective)
San Francisco, CA
GV (Andreessen Bio separate)
Menlo Park, CA
最近の投資シグナル
Boston biotech sector remains strong but undersized relative to AI mega-rounds; over 50% of Boston's largest funded startups in 2024 are biotech/healthcare focused.
出典: Boston Startup Fundraising Looks Strong Only By Pre-AI ParametersClearNote Health raised $52M in Series D for early cancer detection and monitoring tests.
出典: The Week’s 10 Biggest Funding Rounds: Anthropic Dominates In An Otherwise Slower Week For MegaroundsOctant secured a partnership with Bristol Myers Squibb, a major pharmaceutical company, validating its technology and market relevance.
出典: Wilson Sonsini Advises Octant on $80 Million Series B and Partnership with Bristol Myers Squibb - Wilson SonsiniOctant raised $80 million in Series B funding, indicating strong investor confidence in the company's biotech capabilities and commercial potential.
出典: Wilson Sonsini Advises Octant on $80 Million Series B and Partnership with Bristol Myers Squibb - Wilson SonsiniAndreessen Horowitz is increasing its focus and investment activity in the biotech sector, signaling confidence in the space's long-term potential.
出典: Andreessen Horowitz Is Digging Deeper Into Biotech - BuzzFeed NewsUSV lists bio as one of four main investment domains for analyst focus and portfolio development.
出典: USV Analyst Program 2026Orbis Medicines raised EUR 90 million in Series A funding to develop a pipeline of oral macrocycle therapeutics, indicating investor confidence in the company's drug development approach.
出典: Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles - Business WireBiology is becoming more engineerable through AI and biotech tooling, representing a Version One moment where the intersection of deep science and AI creates a significant investable opportunity.
出典: We’re Bio-BullishLaunching a special investment vehicle led by a former bio founder to back earliest-stage biotinkerers working through scientific and technical risk.
出典: We’re Bio-BullishIdeal biotech founders are deeply technical but not traditionally trained in biology, bring outsider perspectives enabled by AI, collaborate with world-class scientists, and focus on commercializing existing research through creative regulatory paths.
出典: We’re Bio-Bullishよくある質問
BioTech 領域に強いVCはどこですか？
VCWorldはBioTechに関連する投資シグナル数・記事数の多い順にVCを並べています。リスト上位はその領域でアクティブにブログ・テーゼ・投資を発信しているファンドです。
BioTech に投資しているVCをどう絞り込めますか？
本ハブページでは BioTech を focusSectors に含むVCのみを表示しています。さらに地域 (/regions/japan など) やステージ (/stages/seriesA など) のハブと組み合わせれば、より絞り込めます。
投資シグナルとは何ですか？
VCの公式ブログ・パートナーのメディア記事をAIで解析し、投資テーゼ・実投資・トレンド・意見の4種類に分類した構造化データです。確信度スコア (0-100%) 付きで提示しています。
BioTech VCの最新のトレンドはどこで見られますか？
右上の「シグナル一覧」と /trends ページで、過去30日間のBioTech関連シグナル一覧と確信度の高いトピックを確認できます。